The combination of anti-CD40 with anti-CSF-1R, which impairs the recruitment of new TAMs towards the tumor, was effective to treat “cold” preclinical tumor models, not responsive to immune checkpoint inhibitors (ICIs). Here, CD40 is linked to neoplasm.